EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma

Kisako Fujiwara, Takayuki Kondo iD, Kentaro Fujimoto, Sae Yumita, Keita Ogawa, Takamasa Ishino, Miyuki Nakagawa, Terunao Iwanaga, Satoshi Tsuchiya, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue und 10 weitere

Journal of Gastroenterology · 2024

DOI: 10.1007/s00535-024-02097-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Kisako Fujiwara und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. Hauptthemen laut MEDLINE: Hypertension, Portal, Carcinoma, Hepatocellular, Liver Neoplasms, Esophageal and Gastric Varices. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the usefulness of contrast-enhanced computed tomography (CECT) in the management of PH-related complications during systemic therapy.

Methods

A total of 669 patients who received systemic therapy as first-line treatment (443 patients for sorafenib, 131 for lenvatinib, and 90 for atezolizumab/bevacizumab [ATZ/BEV]) were enrolled in this retrospective study. Additionally, the lower esophageal intramural vessel diameters (EIV) on CECT and endoscopic findings in 358 patients were compared.

Results

The cutoff values of the EIV diameter on CECT were 3.1 mm for small, 5.1 mm for medium, and 7.6 mm for large varices, demonstrating high concordance with the endoscopic findings. esophageal varices (EV) bleeding predictors include EIV ≥ 3.1 mm and portal vein tumor thrombosis (PVTT). In patients without EV before systemic therapy, factors associated with EV exacerbation after 3 months were EIV ≥ 1.9 mm and ATZ/BEV use. Predictors of hepatic encephalopathy (HE) include the ammonia level or portosystemic shunt diameter ≥ 6.8 mm. The incidence of HE within 2 weeks was significantly higher (18%) in patients with an ammonia level ≥ 73 μmol/L and a portosystemic shunt ≥ 6.8 mm. The exacerbating factors for ascites after 3 months were PVTT and low albumin levels.

Conclusions

Careful management is warranted for patients with risk factors for exacerbation of PH-related complications; moreover, the effective use of CECT is clinically important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalCarcinoma, HepatocellularLiver NeoplasmsEsophageal and Gastric VaricesPhenylurea CompoundsSorafenibBevacizumabHumansMaleFemaleRetrospective StudiesMiddle AgedAgedRisk FactorsTomography, X-Ray ComputedQuinolinesHepatic EncephalopathyAntineoplastic AgentsAdultAged, 80 and overGastrointestinal HemorrhageIncidence

Stichwörter der Autor:innen

Contrast-enhanced computed tomographyDecompensationHepatocellular carcinomaPortal hypertensionSystemic therapy

Substanzen

Phenylurea CompoundslenvatinibSorafenibBevacizumabQuinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. takakondonaika@yahoo.co.jp.
  • Ultrasound Center, Chiba University Hospital, Chiba, Japan. takakondonaika@yahoo.co.jp.
  • Department of Radiology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Ultrasound Center, Chiba University Hospital, Chiba, Japan.

ORCID-Profile: Takayuki Kondo

Zitieren

APA

Fujiwara, K., Kondo, T., Fujimoto, K., Yumita, S., Ogawa, K., Ishino, T., Nakagawa, M., Iwanaga, T., Tsuchiya, S., Koroki, K., Kanzaki, H., Inoue, M., Kobayashi, K., Kiyono, S., Nakamura, M., Kanogawa, N., Ogasawara, S., Nakamoto, S., Chiba, T., …, & Kato, N. (2024). Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02097-9

Vancouver

Fujiwara K, Kondo T, Fujimoto K, Yumita S, Ogawa K, Ishino T, et al. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02097-9

BibTeX
@article{Fujiwara2024,
  author = {Fujiwara, Kisako and Kondo, Takayuki and Fujimoto, Kentaro and Yumita, Sae and Ogawa, Keita and Ishino, Takamasa and Nakagawa, Miyuki and Iwanaga, Terunao and Tsuchiya, Satoshi and Koroki, Keisuke and Kanzaki, Hiroaki and Inoue, Masanori and Kobayashi, Kazufumi and Kiyono, Soichiro and Nakamura, Masato and Kanogawa, Naoya and Ogasawara, Sadahisa and Nakamoto, Shingo and Chiba, Tetsuhiro and Koizumi, Jun and Kato, Jun and Kato, Naoya},
  title = {Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma},
  journal = {Journal of Gastroenterology},
  year = {2024},
  doi = {10.1007/s00535-024-02097-9}
}
Kostenlos starten →